Video

Dr David Rosmarin on Tailored Biologic Treatments, New Vitiligo Research

Author(s):

David Rosmarin, MD, vice chair of research and education, Department of Dermatology, Tufts Medical Center, discusses best practices for choosing biologics, as well as his late-breaking findings on ruxolitinib cream for vitiligo at the 2022 American Academy of Dermatology (AAD) Annual Meeting.

David Rosmarin, MD, vice chair of research and education, Department of Dermatology, Tufts Medical Center, discusses best practices for choosing biologics, as well as his late-breaking findings on ruxolitinib cream for vitiligo at the 2022 American Academy of Dermatology (AAD) Annual Meeting.

Transcript:

What are some best practices for choosing biologics for patients with different dermatological conditions?

For patients who come in to see us who have various conditions, we really try to tailor the biologic treatment to their needs. I don't have an algorithm where I always put every patient on drug X and then drug Y and then drug Z. I really try to hear what's most important to the patient. Is it certain side effects that they're having that they're worried about, or frequency of injections of medication? In that way, we can try to make sure that we give them the best possible treatment that meets their goals.

What can you tell us about your latest research on the efficacy and safety of ruxolitinib cream monotherapy for vitiligo?

So today [Saturday], we released the results of the TRuE-V1 and TRuE-V2 phase 3 program for topical ruxolitinib cream in vitiligo through Week 52. What it showed is that patients get enhanced pigmentation beyond the 6-month mark, with continued improvement through the year.

Related Videos
Jonathan Kurman, MD
Tetyana Kendzerska, MD
Krunal Patel, MD
Scott Manaker,MD
Juan Carlos Martinez, MD
Parth Rali, MD
IMS Recap
Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel
April Armstrong, MD, MPH, chief of dermatology, UCLA
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo